Historically, re-assorted influenza virus vaccine seeds were made by co-infection of the selected strain with the laboratory strain, in the presence of antibodies against the HA and NA of the laboratory strains, to generate re-assorted viruses that had the internal segments of the laboratory strains conferring high-growth properties and the HA and NA of the desired vaccine strain7. Here, XK is linked to coinfection.